COST-EFFECTIVENESS ANALYSIS OF BENDAMUSTINE PLUS RITUXIMAB AS FIRST-LINE TREATMENT FOR PATIENTS WITH FOLLICULAR LYMPHOMA. PRELIMINARY RESULTS

被引：0
|
作者：
Sabater, E. [1 ]
Rueda, A. [2 ]
Salar, A. [3 ]
Lopez-Guillermo, A. [4 ]
Oyagueez, I. [1 ]
Collar, J. M. [5 ]
机构：
[1] Pharmacoecon & Outcomes Res Iberia, Madrid, Spain
[2] Hosp Costa del Sol, Dept Oncol, Marbella, Spain
[3] Hosp del Mar, Hematol Dept, Madrid, Spain
[4] Hosp Clin Barcelona, Hematol Dept, Barcelona, Spain
[5] Mundipharma Pharmaceut, Dept Med, Madrid, Spain
来源：
HAEMATOLOGICA | 2014年 / 99卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
P1270
引用
收藏
页码：487 / 488
页数：2
相关论文
共 50 条
  • [41] Comparative analysis of rituximab or obinutuzumab combined with CHOP in first-line treatment of follicular lymphoma
    Gwladys Claustre
    Coralie Boulanger
    Frédéric Maloisel
    Nelly Etienne-Selloum
    Luc-Matthieu Fornecker
    Eric Durot
    Florian Slimano
    Véronique Graff
    Journal of Cancer Research and Clinical Oncology, 2023, 149 : 1883 - 1893
  • [42] Pembrolizumab Plus Chemotherapy as First-Line Treatment for Advanced Esophageal Cancer: A Cost-Effectiveness Analysis
    Zhu, Youwen
    Liu, Kun
    Ding, Dong
    Zhou, Yangying
    Peng, Libo
    ADVANCES IN THERAPY, 2022, 39 (06) : 2614 - 2629
  • [43] Cost-effectiveness analysis of durvalumab plus chemotherapy as first-line treatment for biliary tract cancer
    Ye, Zhuo-miao
    Xu, Zhe
    Li, Huan
    Li, Qian
    FRONTIERS IN PUBLIC HEALTH, 2023, 11
  • [44] Pembrolizumab Plus Chemotherapy as First-Line Treatment for Advanced Esophageal Cancer: A Cost-Effectiveness Analysis
    Youwen Zhu
    Kun Liu
    Dong Ding
    Yangying Zhou
    Libo Peng
    Advances in Therapy, 2022, 39 : 2614 - 2629
  • [45] Cost-effectiveness analysis of first-line HAART
    Maggiolo, F.
    Di Matteo, S.
    Masini, G.
    Astuti, N.
    Di Filippo, E.
    Bernardini, C.
    Soavi, L.
    Colombo, G.
    JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2012, 15 : 69 - 70
  • [46] Comparative analysis of rituximab or obinutuzumab combined with CHOP in first-line treatment of follicular lymphoma
    Claustre, Gwladys
    Boulanger, Coralie
    Maloisel, Frederic
    Etienne-Selloum, Nelly
    Fornecker, Luc-Matthieu
    Durot, Eric
    Slimano, Florian
    Graff, Veronique
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2023, 149 (05) : 1883 - 1893
  • [47] Updated Results of the Phase III Study of First-Line Bendamustine/Rituximab Versus CHOP plus Rituximab in Patients with Indolent Non-Hodgkin Lymphoma
    不详
    CLINICAL LYMPHOMA & MYELOMA, 2009, 9 (02): : 128 - 129
  • [48] A multicenter randomized trial of Fludarabine and Mitoxantrone (FM) plus Rituximab versus CHOP plus Rituximab as first-line treatment in patients with follicular lymphoma (FL).
    Zinzani, PL
    BLOOD, 2002, 100 (11) : 93A - 93A
  • [49] Cost-effectiveness of obinutuzumab plus bendamustine followed by obinutuzumab monotherapy for the treatment of follicular lymphoma patients who relapse after or are refractory to a rituximab-containing regimen in the US
    Guzauskas, Gregory F.
    Masaquel, Anthony
    Reyes, Carolina
    Bernaards, Coen
    Krivasi, Tania
    Veenstra, David L.
    JOURNAL OF MEDICAL ECONOMICS, 2018, 21 (10) : 960 - 967
  • [50] Cost-effectiveness of lenalidomide plus rituximab versus rituximab monotherapy in patients with previously treated follicular lymphoma: a societal view
    Thielen, Frederick W.
    Kersten, Marie-Jose
    Kuizenga, Pim
    Hoogendoorn, Mels
    Posthuma, Eduardus F. M.
    Stevens, Wendy B. C.
    Uyl-de Groot, Carin A.
    Blommestein, Hedwig M.
    EXPERT REVIEW OF ANTICANCER THERAPY, 2021, 21 (12) : 1411 - 1422
12345